JP5773437B2 - 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物 - Google Patents
鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物 Download PDFInfo
- Publication number
- JP5773437B2 JP5773437B2 JP2011509615A JP2011509615A JP5773437B2 JP 5773437 B2 JP5773437 B2 JP 5773437B2 JP 2011509615 A JP2011509615 A JP 2011509615A JP 2011509615 A JP2011509615 A JP 2011509615A JP 5773437 B2 JP5773437 B2 JP 5773437B2
- Authority
- JP
- Japan
- Prior art keywords
- rhcc10
- nasal
- administered
- pharmaceutical composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 35
- 206010039083 rhinitis Diseases 0.000 title description 44
- 238000011282 treatment Methods 0.000 title description 31
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 title description 4
- 102000055576 human SCGB1A1 Human genes 0.000 title description 4
- 201000009890 sinusitis Diseases 0.000 claims description 49
- 239000003242 anti bacterial agent Substances 0.000 claims description 22
- 239000007921 spray Substances 0.000 claims description 21
- 208000000592 Nasal Polyps Diseases 0.000 claims description 20
- 206010040744 Sinus headache Diseases 0.000 claims description 20
- 229940088710 antibiotic agent Drugs 0.000 claims description 19
- 239000000739 antihistaminic agent Substances 0.000 claims description 15
- 230000000306 recurrent effect Effects 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 229940125715 antihistaminic agent Drugs 0.000 claims description 12
- 239000000850 decongestant Substances 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 229940124581 decongestants Drugs 0.000 claims description 10
- 210000004877 mucosa Anatomy 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 9
- 229940035676 analgesics Drugs 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000000730 antalgic agent Substances 0.000 claims description 7
- 239000003172 expectorant agent Substances 0.000 claims description 7
- 239000008219 nasal excipient Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 5
- 229940066491 mucolytics Drugs 0.000 claims description 5
- 230000002262 irrigation Effects 0.000 claims description 4
- 238000003973 irrigation Methods 0.000 claims description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 229960004217 benzyl alcohol Drugs 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims description 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 230000000510 mucolytic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 46
- 239000003814 drug Substances 0.000 description 46
- 208000024891 symptom Diseases 0.000 description 45
- 239000013566 allergen Substances 0.000 description 39
- 238000009472 formulation Methods 0.000 description 28
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 25
- 230000002354 daily effect Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 19
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- 201000009151 chronic rhinitis Diseases 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 206010009137 Chronic sinusitis Diseases 0.000 description 13
- 239000003246 corticosteroid Substances 0.000 description 13
- 208000035143 Bacterial infection Diseases 0.000 description 11
- 208000022362 bacterial infectious disease Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000012384 transportation and delivery Methods 0.000 description 11
- 230000002411 adverse Effects 0.000 description 10
- 239000000443 aerosol Substances 0.000 description 10
- 230000000172 allergic effect Effects 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 229960001334 corticosteroids Drugs 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229960004784 allergens Drugs 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 210000002850 nasal mucosa Anatomy 0.000 description 8
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 239000002260 anti-inflammatory agent Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 6
- -1 antifungals Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940071648 metered dose inhaler Drugs 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010028735 Nasal congestion Diseases 0.000 description 5
- 206010069493 Perennial allergy Diseases 0.000 description 5
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 206010052015 cytokine release syndrome Diseases 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007922 nasal spray Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 230000001932 seasonal effect Effects 0.000 description 5
- 206010041232 sneezing Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 208000036071 Rhinorrhea Diseases 0.000 description 4
- 206010048908 Seasonal allergy Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 208000037916 non-allergic rhinitis Diseases 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 229960001528 oxymetazoline Drugs 0.000 description 4
- 238000010181 skin prick test Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 235000018185 Betula X alpestris Nutrition 0.000 description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000048 adrenergic agonist Substances 0.000 description 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 3
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000008263 liquid aerosol Substances 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 3
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 206010028741 Nasal inflammation Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 208000036284 Rhinitis seasonal Diseases 0.000 description 2
- 102000003848 Uteroglobin Human genes 0.000 description 2
- 108090000203 Uteroglobin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000001180 ethmoid sinus Anatomy 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- DTPLOCBWAFWYND-UHFFFAOYSA-N Cl.C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 Chemical compound Cl.C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 DTPLOCBWAFWYND-UHFFFAOYSA-N 0.000 description 1
- GXBLWDTVHCKRDC-UHFFFAOYSA-K Cl[Zr](Cl)(Cl)CC1=CC=CC=C1 Chemical compound Cl[Zr](Cl)(Cl)CC1=CC=CC=C1 GXBLWDTVHCKRDC-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000057955 Eosinophil Cationic Human genes 0.000 description 1
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 241000255952 Papilio Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010051496 Rhinalgia Diseases 0.000 description 1
- 102000011274 Secretoglobin Human genes 0.000 description 1
- 108050001520 Secretoglobin Proteins 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 229940087430 biaxin Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 210000000215 ciliated epithelial cell Anatomy 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940089519 levaquin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940072251 zithromax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Marine Sciences & Fisheries (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5286108P | 2008-05-13 | 2008-05-13 | |
| US61/052,861 | 2008-05-13 | ||
| PCT/US2009/043613 WO2009140269A2 (en) | 2008-05-13 | 2009-05-12 | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520894A JP2011520894A (ja) | 2011-07-21 |
| JP2011520894A5 JP2011520894A5 (enExample) | 2012-06-21 |
| JP5773437B2 true JP5773437B2 (ja) | 2015-09-02 |
Family
ID=41319290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509615A Active JP5773437B2 (ja) | 2008-05-13 | 2009-05-12 | 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20110240012A1 (enExample) |
| EP (2) | EP3085382A1 (enExample) |
| JP (1) | JP5773437B2 (enExample) |
| KR (1) | KR20110014199A (enExample) |
| CN (1) | CN102292099A (enExample) |
| AU (1) | AU2009246543B2 (enExample) |
| BR (1) | BRPI0911945A2 (enExample) |
| CA (1) | CA2724277A1 (enExample) |
| IL (1) | IL208940A0 (enExample) |
| MX (1) | MX2010012234A (enExample) |
| NZ (2) | NZ600803A (enExample) |
| WO (1) | WO2009140269A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| CN102292099A (zh) | 2008-05-13 | 2011-12-21 | 科拉森斯公司 | 在鼻炎治疗中使用的重组人cc10及其组合物 |
| US9168285B2 (en) | 2009-10-15 | 2015-10-27 | Therabron Therapeutics, Inc. | Recombinant human CC10 protein for treatment of influenza and ebola |
| EP2488205B1 (en) * | 2009-10-15 | 2016-09-21 | Clarassance, Inc. | Recombinant human cc10 protein for treatment of influenza |
| WO2012170842A2 (en) | 2011-06-09 | 2012-12-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Peptide for protection of allergic respiratory disorders |
| CA2928035C (en) | 2012-12-27 | 2024-07-02 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with p-glycoprotein inhibitors |
| PE20200404A1 (es) * | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| WO2016205430A1 (en) * | 2015-06-15 | 2016-12-22 | Therabron Therapeutics, Inc. | Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke |
| JP7085485B2 (ja) | 2016-01-15 | 2022-06-16 | マサチューセッツ アイ アンド イヤー インファーマリー | 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである |
| CN113543827B (zh) * | 2019-02-27 | 2025-01-21 | 奥蒂卡拉股份有限公司 | 用于治疗鼻、鼻腔鼻窦和鼻咽组织感染和/或炎症的方法 |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| US12295933B2 (en) | 2019-03-25 | 2025-05-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4691009A (en) | 1984-12-26 | 1987-09-01 | Repligen Corporation | Hybrid proteins produced by an ultrahigh prokaryotic expression system |
| WO1987002367A2 (en) | 1985-10-18 | 1987-04-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US4820514A (en) | 1985-12-30 | 1989-04-11 | Texas A&M University System | Low dosage of interferon to enhance vaccine efficiency |
| JP2656944B2 (ja) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
| US5266562A (en) | 1987-11-19 | 1993-11-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-inflammatory agents |
| US5354269A (en) | 1991-12-20 | 1994-10-11 | Fibrogenex, Inc. | Method for treating cancer resections |
| US5491130A (en) | 1992-11-10 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide inhibitors of fibronectin and related collagen-binding proteins |
| US5482930A (en) | 1993-06-09 | 1996-01-09 | The Regents Of The University Of California | Anti-inflammatory composition and method with des-Tyr dynorphin and analogues |
| US5470885A (en) | 1993-09-29 | 1995-11-28 | The Research Foundation Of The State University Of New York | Fluorocarbons as anti-inflammatory agents |
| FR2724665B1 (fr) | 1994-09-16 | 1996-12-20 | Rhone Poulenc Rorer Sa | Procede de production de proteines recombinantes, plasmides et cellules modifiees |
| US5935860A (en) | 1995-03-07 | 1999-08-10 | The George Washington University | Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia |
| US5696092A (en) | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
| WO1997001627A1 (en) | 1995-06-27 | 1997-01-16 | Igen International, Inc. | High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli |
| US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
| WO1997034997A1 (en) | 1996-03-21 | 1997-09-25 | Human Genome Sciences, Inc. | Human endometrial specific steroid-binding factor i, ii and iii |
| AU5253998A (en) | 1996-11-13 | 1998-06-03 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
| US20040047857A1 (en) | 1997-05-28 | 2004-03-11 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US20020160948A1 (en) * | 1998-07-21 | 2002-10-31 | Aprile Pilon | Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| US7122344B2 (en) | 1997-05-28 | 2006-10-17 | Claragen, Inc. | Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| US20030207795A1 (en) | 1997-05-28 | 2003-11-06 | Pilon Aprile L. | Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| US20030008816A1 (en) | 1997-05-28 | 2003-01-09 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US20060025348A1 (en) | 1997-05-28 | 2006-02-02 | Pilon Aprile L | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US6255281B1 (en) | 1997-05-28 | 2001-07-03 | Claragen, Inc. And U.S. Government | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| US20050261180A1 (en) | 1997-05-28 | 2005-11-24 | Pilon Aprile L | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| US20020169108A1 (en) | 1997-05-28 | 2002-11-14 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| JP4949552B2 (ja) | 1998-04-16 | 2012-06-13 | エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド | インテグリンのそれの受容体への結合を阻害するｎ，ｎ−ジ置換アミド |
| WO2000072868A2 (en) | 1999-06-01 | 2000-12-07 | Prendergast Patrick T | Peptides for therapeutic use |
| AU1582401A (en) | 1999-11-04 | 2001-05-14 | Human Genome Sciences, Inc. | Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| CA2405946A1 (en) | 2000-04-14 | 2001-10-25 | Claragen, Inc. | Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production |
| US20020025510A1 (en) | 2000-07-26 | 2002-02-28 | Strongin Alex Y. | Screening methods based on superactivated alpha V beta 3 integrin |
| WO2003057257A1 (en) * | 2002-01-02 | 2003-07-17 | The Johns Hopkins University | Cc10 inhibits th2 cytokines and eotaxins involved in allergic diseases |
| US20090227025A1 (en) | 2003-06-06 | 2009-09-10 | The Board Of Regents Of The University Of Texas System | Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism |
| EP1789067B8 (en) * | 2004-08-12 | 2012-08-15 | Helsinn Healthcare S.A. | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system |
| EP2086560A4 (en) * | 2006-11-02 | 2012-03-28 | Riolan Technologies Inc | METHODS OF TREATING EPIPHORA |
| EP1935242A1 (en) * | 2006-12-21 | 2008-06-25 | Philip Morris Products S.A. | Transgenic animal model |
| WO2009126623A2 (en) | 2008-04-08 | 2009-10-15 | Amyris Biotechnologies, Inc. | Expression of heterologous sequences |
| CN102292099A (zh) | 2008-05-13 | 2011-12-21 | 科拉森斯公司 | 在鼻炎治疗中使用的重组人cc10及其组合物 |
| EP2488205B1 (en) | 2009-10-15 | 2016-09-21 | Clarassance, Inc. | Recombinant human cc10 protein for treatment of influenza |
-
2009
- 2009-05-12 CN CN2009801169194A patent/CN102292099A/zh active Pending
- 2009-05-12 EP EP16164414.1A patent/EP3085382A1/en not_active Withdrawn
- 2009-05-12 WO PCT/US2009/043613 patent/WO2009140269A2/en not_active Ceased
- 2009-05-12 KR KR1020107028003A patent/KR20110014199A/ko not_active Ceased
- 2009-05-12 NZ NZ600803A patent/NZ600803A/en not_active IP Right Cessation
- 2009-05-12 AU AU2009246543A patent/AU2009246543B2/en not_active Ceased
- 2009-05-12 EP EP09747353A patent/EP2303308A4/en not_active Ceased
- 2009-05-12 CA CA2724277A patent/CA2724277A1/en not_active Abandoned
- 2009-05-12 NZ NZ588895A patent/NZ588895A/en not_active IP Right Cessation
- 2009-05-12 MX MX2010012234A patent/MX2010012234A/es active IP Right Grant
- 2009-05-12 JP JP2011509615A patent/JP5773437B2/ja active Active
- 2009-05-12 BR BRPI0911945A patent/BRPI0911945A2/pt not_active IP Right Cessation
-
2010
- 2010-10-26 IL IL208940A patent/IL208940A0/en unknown
- 2010-11-12 US US12/945,622 patent/US20110240012A1/en not_active Abandoned
-
2016
- 2016-02-12 US US15/042,790 patent/US9844580B2/en active Active
-
2017
- 2017-11-10 US US15/809,357 patent/US20180125931A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009140269A2 (en) | 2009-11-19 |
| AU2009246543A1 (en) | 2009-11-19 |
| AU2009246543B2 (en) | 2015-08-06 |
| US9844580B2 (en) | 2017-12-19 |
| US20180125931A1 (en) | 2018-05-10 |
| EP2303308A4 (en) | 2012-11-07 |
| IL208940A0 (en) | 2011-01-31 |
| CN102292099A (zh) | 2011-12-21 |
| KR20110014199A (ko) | 2011-02-10 |
| US20160158315A1 (en) | 2016-06-09 |
| JP2011520894A (ja) | 2011-07-21 |
| CA2724277A1 (en) | 2009-11-19 |
| EP2303308A2 (en) | 2011-04-06 |
| BRPI0911945A2 (pt) | 2015-10-13 |
| WO2009140269A3 (en) | 2011-10-27 |
| NZ600803A (en) | 2013-12-20 |
| MX2010012234A (es) | 2011-03-03 |
| NZ588895A (en) | 2012-07-27 |
| US20110240012A1 (en) | 2011-10-06 |
| EP3085382A1 (en) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5773437B2 (ja) | 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物 | |
| AU2002361918B2 (en) | Aerosolized decongestants for the treatment of sinusitis | |
| AU779077B2 (en) | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis | |
| AU2002361918A1 (en) | Aerosolized decongestants for the treatment of sinusitis | |
| KR100810872B1 (ko) | 감기 치료용 조성물 | |
| WO2011047065A1 (en) | Recombinant human cc10 protein for treatment of influenza | |
| US9023815B2 (en) | Method for treating rhinitis and sinusitis by rhamnolipids | |
| MX2007001561A (es) | Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas. | |
| AU2015204387A1 (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
| US20240197771A1 (en) | Compositions and uses thereof | |
| Whittaker | Chronic sinusitis: OTC management | |
| Van Schoor | Colds, flu and coughing: a review of over-the-counter nasal therapies in general practice | |
| Strauss | Complications from Flu-an unnecessary evil! How to treat and manage patients suffering from influenza in order to prevent unnecessary complications and adverse outcomes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120507 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130828 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150601 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150625 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5773437 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |